Navigation Links
Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Date:3/13/2009

NEW YORK, March 13 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually. Applications will be accepted twice a year, with up to $2.5 million in funding available each spring and another $2.5 million available in the fall.

First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.

Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.

The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly $12.8 million total under the initiative for 24 industry-led projects.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly $140 million in research directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gene Network Sciences Announces Michael Gilman as Board Member
2. Nyenrode Honorary Doctorate for Professor Michael E. Porter
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
5. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decades Real Nutritional Heroes
8. Xceleron Names Michael Butler as President & CEO
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):